Several meta-analyses based on clinical trials have shown that patients who achieve a pCR following NAC have better survival and lower disease recurrence rates, especially if they had an aggressive, HER2-positive or triple negative breast cancer subtype [24]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.